The role of metabolic syndrome in sudden cardiac death risk: Recent evidence and future directions. (8th November 2021)

• Record Type: Journal Article
• Authors: Tirandi, Amedeo; Carbone, Federico; Montecucco, Fabrizio; Liberale, Luca
• Is Part Of: European journal of clinical investigation. Volume 52:Number 2(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-11-08
• Subjects: dyslipidemia -- hypertension -- metabolic syndrome -- sudden cardiac death; Pathology -- Periodicals; Medical research -- Periodicals; 616.075
• DOI: 10.1111/eci.13693
• Languages: English
• ISSNs: 0014-2972

Abstract

Abstract: Metabolic syndrome (MetS) is a frequent condition whose deleterious effects on the cardiovascular system are often underestimated. MetS is nowadays considered a real pandemic with an estimated prevalence of 25% in general population. Individuals with MetS are at high risk of sudden cardiac death (SCD) as this condition accounts for 50% of all cardiac deaths in such a population. Of interest, recent studies demonstrated that individuals with MetS show 70% increased risk of SCD even without previous history of coronary heart disease (CHD). However, little is known about the interplay between the two conditions. MetS is a complex disease determined by genetic predisposition, unhealthy lifestyle and ageing with deleterious effects on different organs. MetS components trigger a systemic chronic low‐grade pro‐inflammatory state, associated with excess of sympathetic activity, cardiac hypertrophy, arrhythmias and atherosclerosis. Thus, MetS has an important burden on the cardiovascular system as demonstrated by both preclinical and clinical evidence. The aim of this review is to summarize recent evidence concerning the association between MetS and SCD, showing possible common aetiological processes, and to indicate prospective for future studies and therapeutic targets.